PHMB PharmaCom BioVet Inc (CE)

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce the company is now beginning the process of locating commercial sites throughout the continental United States to begin the full scale build out of the nation's first branded dedicated Veterinary Oncology Centers.

These centers are going to provide cancer treatment to companion animals using licensed proprietary technologies. PharmaCom BioVet, Inc. expects to garner a significant market share of the overwhelming 41 billion dollar per year veterinary market as the result of early efforts put in by management in seeking out superior treatments and devices.

According to Sharon Berthold, Executive Vice President of PharmaCom BioVet, Inc., "Recent collaborations with world renowned veterinary oncology specialists have allowed us the opportunity to create what I believe are the foremost in companion animal oncology treatments. Recent financial commitments from Investment bankers have allowed us the opportunity to build out our centers on a national scale. We will be concentrating heavily on the branding of PharmaCom BioVet, Inc. using a marketing plan which includes commercials and literature to be distributed to veterinary partners."

About Us:

PharmaCom BioVet, Inc. (PHMB) is quickly positioning itself to become the leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management is planning the rollout of specialized veterinary oncology treatment centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer greater life expectancy and decreased suffering.

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact: Investor Relations 919-572-6395 investors@pharmacombiovet.com